BFRI BIOFRONTERA INC

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time.

Conference Call and Webcast Information

DateFriday, March 21, 2025
Time10:00 AM Eastern Time
Dial In Numbers1-877-877-1275 (U.S.)

1-412-858-5202 (international)
Webcast



About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit and follow Biofrontera on  and .

Contacts:

Investor Relations

Andrew Barwicki

1-516-662-9461

SOURCE: Biofrontera Inc.



EN
11/03/2025

Underlying

BFRIBIOFRONTERA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOFRONTERA INC

 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3...

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremitiesProtocol involves one or two PDT treatments using 1-3 tubes of Ameluz® or vehicle gel over a surface area of up to 240 cm2Treatment phase expected to be complete by Q3 2025 WOBURN, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biophar...

March 18, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial...

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025 WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time. Conference...

March 11, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Stu...

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be included in FDA submission, expected in Q3 2025.Biofrontera announced highly statistically significant results for all primary and secondary endpoints (p

January 8, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible note (the “Note”) with its principal shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s assets. The principal amoun...

November 22, 2024 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial R...

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update  ●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton.    ●Total revenues for the first 9 months were $24.8 million, an increase of $1.3 million, or 5.6% as compared to the same period last year. Without the impact of Hurricane Milton delaying shipments, the increase would have been 12%.    ●Ameluz® achieved record volume in September 2024.      ●Organiza...

November 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch